^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DF9001

    i
    Other names: DF9001
    Associations

    News

    Trials
    Company:
    Dragonfly Therap
    Drug class:
    EGFR inhibitor, NK cell stimulant
    Related drugs:
    Associations

    News

    Trials
    6ms
    Study of DF9001 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=242, Recruiting, Dragonfly Therapeutics | N=362 --> 242 | Trial completion date: Dec 2026 --> Nov 2027 | Trial primary completion date: Oct 2024 --> Aug 2025
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    RET mutation • RAS wild-type
    |
    Keytruda (pembrolizumab) • DF9001
    9ms
    Study of DF9001 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=362, Recruiting, Dragonfly Therapeutics | Trial primary completion date: Oct 2023 --> Oct 2024
    Trial primary completion date • Combination therapy • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    RET mutation • RAS wild-type
    |
    Opdivo (nivolumab) • DF9001
    almost2years
    Study of DF9001 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=362, Recruiting, Dragonfly Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    RET mutation • RAS wild-type
    |
    Opdivo (nivolumab) • DF9001
    2years
    Study of DF9001 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=362, Not yet recruiting, Dragonfly Therapeutics
    New P1/2 trial • Combination therapy • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    RET mutation • RAS wild-type
    |
    Opdivo (nivolumab) • DF9001